John R. Feussner

A method for assessing drug therapy appropriateness

This study evaluated the reliability of a new medication appropriateness index. Using the index, independent assessments were made of chronic medications taken by 10 ambulatory, elderly male patients by a clinical pharmacist and an internist-geriatrician. Their overall inter-rater agreement for medication appropriateness (ppos) was 0.88, and for medication inappropriateness (pneg) was 0.95; the overall kappa was 0.83. Their intra-rater agreement for ppos was 0.94 overall, for pneg was 0.98 overall while the overall kappa was 0.92. The chronic medications taken by 10 different ambulatory elderly male patients were independently evaluated by two different clinical pharmacists. Their overall inter-rater agreement for ppos was 0.76, and for pneg was 0.93, while the overall kappa was 0.59. This new index provides a reliable method to assess drug therapy appropriateness. Its use may be applicable as a quality of care outcome measure in health services research and in institutional quality assurance programs.

Measurement of motor recovery after stroke. Outcome assessment and sample size requirements.

Background and Purpose The purpose of this study was to analyze recovery of motor function in a cohort of patients presenting with an acute occlusion in the carotid distribution. Analysis of recovery patterns is important for estimating patient care needs, establishing therapeutic plans, and estimating sample sizes for clinical intervention trials. Methods We prospectively measured the motor deficits of 104 stroke patients over a 6-month period to identify earliest measures that would predict subsequent motor recovery. Motor function was measured with the Fugl-Meyer Assessment. Fifty-four patients were randomly assigned to a training set for model development; 50 patients were assigned to a test set for model validation. In a second analysis, patients were stratified on basis of time and stroke severity. The sample size required to detect a 50% improvement in residual motor function was calculated for each level of impairment and at three points in time. Results At baseline the initial Fugl-Meyer motor scores accounted for only half the variance in 6-month motor function (r2=0.53, p<0.001). After 5 days, both the 5-day motor and sensory scores explained 74% of the variance (p<0.001). After 30 days, the 30-day motor score explained 86% of the variance (p<0.001). Application of these best models to the test set confirmed the results obtained with the training set. Sample-size calculations revealed that as severity and time since stroke increased, sample sizes required to detect a 50% improvement in residual motor deficits decreased. Conclusions Most of the variability in motor recovery can be explained by 30 days after stroke. These findings have important implications for clinical practice and research.

A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy

PURPOSE To evaluate the effect of sustained clinical pharmacist interventions involving elderly outpatients with polypharmacy and their primary physicians. PATIENTS AND METHODS Randomized, controlled trial of 208 patients aged 65 years or older with polypharmacy (> or = 5 chronic medications) from a general medicine clinic of a Veterans Affairs Medical Center. A clinical pharmacist met with intervention group patients during all scheduled visits to evaluate their drug regimens and make recommendations to them and their physicians. Outcome measures were prescribing appropriateness, health-related quality of life, adverse drug events, medication compliance and knowledge, number of medications, patient satisfaction, and physician receptivity. RESULTS Inappropriate prescribing scores declined significantly more in the intervention group than in the control group by 3 months (decrease 24% versus 6%, respectively; P = 0.0006) and was sustained at 12 months (decrease 28% versus 5%, respectively; P = 0.0002). There was no difference between groups at closeout in health-related quality of life (P = 0.99). Fewer intervention than control patients (30.2%) versus 40.0%; P = 0.19) experienced adverse drug events. Measures for most other outcomes remained unchanged in both groups. Physicians were receptive to the intervention and enacted changes recommended by the clinical pharmacist more frequently than they enacted changes independently for control patients (55.1% versus 19.8%; P <0.001). CONCLUSIONS This study demonstrates that a clinical pharmacist providing pharmaceutical care for elderly primary care patients can reduce inappropriate prescribing and possibly adverse drug effects without adversely affecting health-related quality of life.

A nurse-coordinated intervention for primary care patients with non-insulin-dependent diabetes mellitus: impact on glycemic control and health-related quality of life

AbstractOBJECTIVE: To examine the impact of a nurse-coordinated intervention delivered to patients with non-insulin-dependent diabetes mellitus between office visits to primary care physicians. DESIGN: Randomized, controlled trial. SETTING: Veterans Affairs general medical clinic. PATIENTS: 275 veterans who had NIDDM and were receiving primary care from general internists. INTERVENTION: Nurse-initiated contacts were made by telephone at least monthly to provide patient education (with special emphasis on regimens and significant signs and symptoms of hyperglycemia and hypoglycemia), reinforce compliance with regimens, monitor patients’ health status, facilitate resolution of identified problems, and facilitate access to primary care. MEASUREMENTS: Glycemic control was assessed using glycosylated hemoglobin (GHb) and fasting blood sugar (FBS) levels. Health-related quality of life (HRQOL) was measured with the Medical Outcomes Study SF-36, and diabetes-related symptoms were assessed using patients’ self-reports of signs and symptoms of hyper- and hypoglycemia during the previous month. MAIN RESULTS: At one year, between-group differences favored intervention patients for FBS (174.1 mg/dL vs 193.1 mg/dL, p=0.011) and GHb (10.5% vs 11.1%, p=0.046). Statistically significant differences were not observed for either SF-36 scores (p=0.66) or diabetes-related symptoms (p=0.23). CONCLUSIONS: The intervention, designed to be a pragmatic, low-intensity adjunct to care delivered by physicians, modestly improved glycemic control but not HRQOL or diabetes-related symptoms.

The Role of Antineutrophil Cytoplasmic Antibody (c-ANCA) Testing in the Diagnosis of Wegener Granulomatosis: A Literature Review and Meta-analysis

Wegener granulomatosis is a serious systemic vasculitis that is uniformly fatal if untreated. In 1983, Fauci and colleagues [1] reported their success with a combination of corticosteroid and cyclophosphamide therapy in 85 patients with Wegener granulomatosis. Since then, the recognition among clinicians of Wegener granulomatosis and its expanded clinical spectrum has improved, making early diagnosis and treatment possible. Patients with the classic Wegener triad have necrotizing granulomatous vasculitis of the upper and lower respiratory tract associated with glomerulonephritis; patients with limited Wegener granulomatosis may have vasculitis limited to the respiratory tract [2]. Because of the potential clinical overlap with other diseases, the diagnostic algorithm for patients with suspected Wegener granulomatosis has traditionally included biopsy of the upper airway, lung, or kidney to confirm the diagnosis and to rule out other entities, such as systemic infections and malignancies, that may respond adversely to cyclophosphamide therapy [3]. Antineutrophil cytoplasmic antibody (ANCA), first described in 1982 in patients with systemic vasculitis and glomerulonephritis, has emerged as a new diagnostic tool and marker of disease activity for vasculitis [4, 5]. Originally thought to be a response to arboviral infection, ANCA was later identified as a seromarker for Wegener granulomatosis [4, 6]. It is currently believed that the presence of ANCA is an important factor in the pathogenesis of this disease [5]. Two ANCA patterns may be seen with indirect immunofluorescence of ethanol-fixed neutrophils: a cytoplasmic pattern (c-ANCA) and the artifactual perinuclear pattern (p-ANCA) [7, 8]. The major antigen for c-ANCA is a 29-kd serine protease, known as proteinase 3, which is found within the azurophilic granules of the neutrophil [9]. The major antigen for p-ANCA is myeloperoxidase, a lysosomal enzyme found in neutrophils [7, 10]. Some clinical overlap has been seen, but the two patterns have different disease associations. The c-ANCA pattern has predominantly been associated with Wegener granulomatosis, and p-ANCA has been associated with microscopic polyarteritis, other vasculitides, idiopathic necrotizing and crescentic glomerulonephritis, and other diseases [7, 11-13]. Early studies of c-ANCA in patients with Wegener granulomatosis, especially those with active disease, have been promising. Reported sensitivities and specificities have exceeded 90% [10-12, 14-18]. Because of the morbidity and expense associated with biopsy, c-ANCA has attracted interest as a rapid and noninvasive way to diagnose Wegener granulomatosis. In fact, some investigators advocate immunosuppressive therapy for patients with positive c-ANCA test results and symptoms compatible with Wegener granulomatosis, even in the absence of biopsy results [19-21]. The history of c-ANCA testing appears to mirror the natural history of many new diagnostic tests. Important and early pioneering studies of new tests are typically done in highly selected patients with confirmed disease to determine the tests operating characteristics. However, when the new test is subsequently applied to unselected populations, clinical experience and additional studies often provide a less optimistic picture of its diagnostic power. Several recent reports [22-27] document false-positive c-ANCA test results in patients with tuberculosis, Hodgkin lymphoma, human immunodeficiency virus infection, nasal septal perforation, monoclonal gammopathies, and drug-induced Wegener-like disease. Similarly, additional reports [28, 29] describe negative c-ANCA test results in patients with Wegener granulomatosis, even those with active disease. Given the current enthusiasm for a serologic diagnosis of Wegener granulomatosis, underrecognition of the rate of false-positive c-ANCA test results may lead to inappropriate immunosuppressive therapy in some patients who do not have Wegener granulomatosis. Conversely, underappreciation of the frequency of false-negative c-ANCA test results may delay therapy for patients who have clinical features compatible with Wegener granulomatosis. We did a literature review and meta-analysis to assess the utility of c-ANCA as a diagnostic marker for Wegener granulomatosis overall and in relation to disease activity. Methods As noted above, two ANCA patterns have been described in the literature, and each has separate disease associations. Patients with Wegener granulomatosis often have c-ANCA, whereas p-ANCA is found in patients with various syndromes with and without vasculitis [7, 30, 31]. Because c-ANCA is thought to have a higher test sensitivity than p-ANCA for the diagnosis of Wegener granulomatosis, we focused only on c-ANCA. Search Strategy We could not determine a systematic approach for identifying unpublished data on c-ANCA, and thus we selected only published articles for our literature review. We did a MEDLINE search for English-language studies done in humans and published between 1966 and June 1993. Three searches were done: 1) a textword and registry search for antineutrophil cytoplasmic antibody [ANCA], anticytoplasmic antibody, and antineutrophil antibody; 2) a combination of search terms antibodies, neutrophils and keywords such as pulmonary-renal syndrome, or Wegener granulomatosis, or vasculitis, or glomerulonephritis; and 3) a search using the keyword pulmonary-renal syndrome alone. Using this initial search strategy, we identified 720 citations. Manual examination of the reference lists of included articles and the bibliographies of review articles and standard texts yielded an additional 27 studies, for a total of 747. Article Selection To be included in the analysis, all articles had to pass through a four-stage review (Table 1). First, the titles and abstracts of the 747 articles were independently examined by two reviewers. One reviewer was a rheumatologist, and the other was a health services researcher with a PhD who had experience in the critical appraisal of medical literature. Articles were excluded at this stage if they were not pertinent to the topic (for example, if they addressed antineutrophil antibodies and malignancy) or if they did not present patient-level data (for example, if they were reports of tissue culture experiments). If a cited article did not have a published abstract but appeared to be relevant, or if either reviewer included it, it was retained for further review. Of the original 747 articles, 407 were excluded and 340 were retained for second-level review. Table 1. Summary of the Results of Protocol for Selection of Articles for Meta-analysis In stage 2 of the review process, the complete articles were photocopied and reviewed by a rheumatologist. Articles were excluded if they were case reports (n = 64), reviews (n = 75), or letters to the editor (n = 58), or if they were irrelevant to our topic (n = 81). Sixty-two of the 340 articles remained for potential inclusion. In stage 3, a rheumatologist (JKR) and an investigator with a PhD reviewed the methods section of each article in detail. The methodologic criteria required for inclusion at this stage were specification of the patient selection method and the use of standard reference criteria to define Wegener granulomatosis. For casecontrol and cohort studies, the authors had to have described a systematic method of patient selection (for example, consecutive patients or a random sample based on prespecified criteria) [32]. Thus, case-series studies (such as those defining persons with a common feature nonsystematically without the presence of a control group) were excluded. Authors also had to specify standard reference criteria for establishing Wegener granulomatosis exclusive of the c-ANCA test result. Acceptable reference criteria included the Ear, Nose, Throat, Lung, and Kidney staging system [2], the Fauci criteria [1], and the American College of Rheumatology criteria [33]. The Ear, Nose, Throat, Lung, and Kidney system and the American College of Rheumatology criteria require biopsy confirmation of Wegener granulomatosis, and the Fauci criteria are clinicopathologic in nature. Thirty-nine articles were excluded at this stage for the following reasons: case-series design (n = 24); the method of patient selection was not clearly stated (n = 4); a reference standard was not specified (n = 7); or the article was irrelevant to our review (n = 4). If either reader included an article, it was retained for further review. In stage 4, three physicians each independently read the remaining 23 articles. Articles were excluded at this stage if a 2 2 contingency table, needed to calculate the operating characteristics, could not be constructed from the results (n = 8). Thus, 15 articles remained for detailed review [10, 11, 14, 15, 28, 34-43]. For these 15 articles, 2 2 contingency tables were constructed for patients with and without Wegener granulomatosis compared with patients with and without positive c-ANCA test results. Disagreements between reviewers were resolved by consensus. Definition of Wegener Granulomatosis We included only those studies that specified standard reference criteria for defining Wegener granulomatosis independent of the patients c-ANCA test result [1, 2, 33]. Patients with Wegener granulomatosis can be further divided into two subtypes: those with classic and those with limited disease [2]. In classic Wegener granulomatosis, glomerulonephritis and inflammation of the upper or lower respiratory tract, or both, are present. In limited disease, the kidneys are not involved, but inflammation of the upper or lower respiratory tract, or both, is present. Only 6 of the 15 studies separated patients by subtype. Furthermore, 2 of these 6 studies did not separate the c-ANCA test results by Wegener granulomatosis subtype. Because of these inconsistencies, we considered a single classification (overall Wegener granulomatosis) to repres

Reinventing VA health care: Systematizing quality improvement and quality innovation

The Veterans Health Administration (VHA) in the US Department of Veterans Affairs (VA) manages the largest fully integrated health care system in the United States. In 1995, the VHA initiated a reinvention effort that included the most radical redesign of VA health care to occur since the veterans health care system was formally established in 1946. The 2 paramount goals of this reinvention effort were to ensure the predictable and consistent provision of high-quality care everywhere in the system and to optimize the value of VA health care. Although still a work in progress, dramatic results have been achieved toward these ends during the past 5 years. This article provides an overview of the veterans health care system, and it highlights selected aspects of the systems reengineering. It also describes various steps that have been taken to better manage performance and to systematize quality improvement and quality innovation. This information provides a global context that should facilitate understanding of the genesis and purposes of the Quality Enhancement Research Initiative that is described in other articles in this issue of Medical Care.

The relationship between glycemic control and health-related quality of life in patients with non-insulin-dependent diabetes mellitus.

The relationship between glycemic control and health-related quality of life was examined in patients with non-insulin-dependent diabetes mellitus (NIDDM). Within the context of a randomized controlled trial, 275 patients with NIDDM receiving primary care from a Veterans Administration general medical clinic were enrolled and monitored for 1 year. Glycemic control (glycosylated hemoglobin levels) and health-related quality of life (Medical Outcomes Study Short-Form 36-item Health Survey [SF-36]) were assessed at baseline and at 1 year. Multivariate regression modeling using baseline and change scores during a 1− year period did not find a linear or curvilinear relationship between glycosylated hemoglobin and SF-36 scores (P = .15); this was true even after controlling for five covariates identified a priori (insulin use, number of diabetic complications, duration of diabetes, education, number of hyper-, or hypoglycemic episodes during the preceding month). Health services researchers and clinicians alike need to be aware that these two important outcomes may not be directly related. This lack of association could contribute to the high noncompliance rates observed among patients prescribed complex diabetic regimens. Unless patients perceive a benefit from following such regimens, good glycemic control may continue to be an elusive therapeutic goal, especially in patients with long-standing disease.

Appropriateness of Medication Prescribing in Ambulatory Elderly Patients

OBJECTIVE: To assess the quality of medication prescribing in ambulatory elderly patients on multiple medications using the Medication Appropriateness Index (MAI).

Quality Enhancement Research Initiative (QUERI): A collaboration between research and clinical practice

This article provides an overview of the Quality Enhancement Research Initiative (QUERI), an ambitious attempt to develop a data-driven national quality-improvement program for the Veterans Health Administration (VHA) that is fully integrated within VHAs Strategic Framework for Quality Management, as discussed elsewhere in this supplement. QUERI is designed to ensure the systematic translation of findings and products (quality tools that promote use of research findings) to promote optimal patient outcomes and system-wide improvements. In developing QUERI, a framework was created to integrate structural elements (organizational characteristics) and process considerations (those actions and action sequences associated with positive change) with outcomes (both at the patient level and at the systems level). In developing this framework, a process for translation of evidence into action was born. The QUERI process depends on having or discovering accurate information about what services are needed, who needs them, how they should be provided, and relevant outcomes and costs. This article describes the 6-step QUERI process and presents an overview of relevant programmatic details, including QUERIs rigorous review process, and VHAs unique qualifications for establishing a national model for quality improvement.

Intermediate, Indeterminate, and Uninterpretable Diagnostic Test Results

Diagnostic tests do not always yield positive or negative results; sometimes the results are intermediate, indeterminate, or uninterpretable. No consensus exists for the incorporation of such results into data assessment. Conventional Bayesian analysis leads investigators to either exclude patients with non-positive, non-negative results from their studies or categorize such results into inappropriate cells of the standard four-cell decision matrix. The authors propose a standardized method for reporting results in studies dealing with diagnostic test use and discuss how researchers should expand the four-cell matrix to six cells when non- positive, non-negative results occur. They suggest that the six-cell matrix with new operational definitions of sensitivity, specificity, likelihood ratios, and test yield should be adopted rou tinely. In addition, they define the different types of non-positive, non-negative results and demonstrate how clinicians can use tree-structured decision analysis from the six-cell matrix. While their method does not solve all problems posed by non-positive, non-negative results, it does suggest a standard method for reporting these results and utilizing all the data in decision making. Key words: diagnostic tests, Bayes theorem, decision analysis. (Med Decis Making 7:107-114, 1987)